Matthew Fust Biography and Net Worth

Director of Neumora Therapeutics

Matthew Fust is a board member and advisor to life sciences companies. Mr. Fust was previously executive vice president and chief financial officer of Onyx Pharmaceuticals. Prior to Onyx, Matthew held the position of chief financial officer for Jazz Pharmaceuticals and Perlegen Sciences and before that, was senior vice president and chief financial officer at ALZA Corporation, where he was an executive from 1996 until 2002.

Matthew currently serves on the boards of directors of Atara Biotherapeutics, Crinetics Pharmaceuticals and Ultragenyx Pharmaceutical.

He holds a B.A. from the University of Minnesota and an MBA from the Stanford University Graduate School of Business.

What is Matthew K. Fust's net worth?: The estimated net worth of Matthew K. Fust is at least $50.92 thousand as of September 26th, 2025. Fust owns 22,836 shares of Neumora Therapeutics stock worth more than $50,924 as of April 23rd. This net worth evaluation does not reflect any other investments that Fust may own. Learn More about Matthew K. Fust's net worth.
How do I contact Matthew K. Fust?: The corporate mailing address for Fust and other Neumora Therapeutics executives is , , . Neumora Therapeutics can also be reached via phone at 857-760-0900 and via email at [email protected]. Learn More on Matthew K. Fust's contact information.
Has Matthew K. Fust been buying or selling shares of Neumora Therapeutics?: Matthew K. Fust has not been actively trading shares of Neumora Therapeutics during the past quarter. Most recently, Matthew K. Fust sold 14,049 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a transaction totalling $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company's stock, valued at $342,303. Learn More on Matthew K. Fust's trading history.
Who are Neumora Therapeutics' active insiders?: Neumora Therapeutics' insider roster includes Kristina Burow (Director), Matthew Fust (Director), and Joshua Pinto (President). Learn More on Neumora Therapeutics' active insiders.
Are insiders buying or selling shares of Neumora Therapeutics?: In the last twelve months, Neumora Therapeutics insiders bought shares 2 times. They purchased a total of 3,831,400 shares worth more than $9,999,954.00. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 138,090 shares worth more than $390,051.47. The most recent insider tranaction occured on February, 17th when insider Daljit Singh Aurora sold 6,165 shares worth more than $21,947.40. Insiders at Neumora Therapeutics own 26.8% of the company. Learn More about insider trades at Neumora Therapeutics.
Information on this page was last updated on 2/17/2026.

Matthew K. Fust Insider Trading History at Neumora Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/18/2024	Sell	14,049	$17.03	$239,254.47	20,100

Matthew K. Fust Buying and Selling Activity at Neumora Therapeutics

Neumora Therapeutics Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.23

$2.19

$2.31

50 Day Range

MA: $2.71

$1.93

$3.59

2 Week Range

Now: $2.23

$0.61

$3.65

Volume

1,186,866 shs

Average Volume

1,626,863 shs

Market Capitalization

$407.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.08